129 related articles for article (PubMed ID: 15269784)
1. Arsenic trioxide: expanding roles for an ancient drug?
Ravandi F
Leukemia; 2004 Sep; 18(9):1457-9. PubMed ID: 15269784
[No Abstract] [Full Text] [Related]
2. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
Rousselot P; Larghero J; Arnulf B; Poupon J; Royer B; Tibi A; Madelaine-Chambrin I; Cimerman P; Chevret S; Hermine O; Dombret H; Claude Brouet J; Paul Fermand J
Leukemia; 2004 Sep; 18(9):1518-21. PubMed ID: 15269785
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
[TBL] [Abstract][Full Text] [Related]
4. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
5. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Kalmadi SR; Hussein MA
Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
[TBL] [Abstract][Full Text] [Related]
7. Overview of drug therapy for multiple myeloma.
Saunders G
J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide for the treatment of myelodysplastic syndromes.
Vey N
Expert Opin Pharmacother; 2004 Mar; 5(3):613-21. PubMed ID: 15013929
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
Röllig C; Illmer T
Cancer Treat Rev; 2009 Aug; 35(5):425-30. PubMed ID: 19464807
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials referral resource. Clinical trials with arsenic trioxide.
Murgo AJ; McBee WL; Cheson BD
Oncology (Williston Park); 2000 Feb; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
[No Abstract] [Full Text] [Related]
11. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide: an emerging therapy for multiple myeloma.
Munshi NC
Oncologist; 2001; 6 Suppl 2():17-21. PubMed ID: 11331436
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide in multiple myeloma: rationale and future directions.
Anderson KC; Boise LH; Louie R; Waxman S
Cancer J; 2002; 8(1):12-25. PubMed ID: 11895198
[TBL] [Abstract][Full Text] [Related]
14. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
Dalton WS
Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
[No Abstract] [Full Text] [Related]
15. Novel biologically based therapies for multiple myeloma.
Munshi NC; Hideshima T; Chauhan D; Richardson P; Anderson KC
Int J Hematol; 2002 Aug; 76 Suppl 1():340-1. PubMed ID: 12430878
[No Abstract] [Full Text] [Related]
16. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
17. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
Nouri K; Ricotti CA; Bouzari N; Chen H; Ahn E; Bach A
J Drugs Dermatol; 2006 Feb; 5(2):182-5. PubMed ID: 16485889
[TBL] [Abstract][Full Text] [Related]
18. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
Berenson JR; Yeh HS
Clin Lymphoma Myeloma; 2006 Nov; 7(3):192-8. PubMed ID: 17229334
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lo Coco F
Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655
[No Abstract] [Full Text] [Related]
20. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
